Alkermes(ALKS)
Focus: Alkermes is a mid-cap biotechnology company headquartered in Dublin focused on small-molecule therapeutics for neurology, psychiatry, and addiction. Public company (NASDAQ: ALKS) with ~$1.7B FY2025 revenue and 16% R&D intensity.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
25
Should You Work at Alkermes?
AI assessmentSolid choice for commercial, regulatory, or medical affairs careers if you value stability and established brands, but risky for R&D professionals seeking deep innovation or career growth in a shrinking pipeline.
Why Work Here
- Strong cash generation ($356M net income FY2025) and peak-stage commercial products (ARISTADA, LYBALVI, VIVITROL) provide stability and opportunities across commercial, medical affairs, and regulatory functions.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 in 5yr
VIVITROL
Hiring
Stable
Revenue
$1.7B
Key Products
$273M Part DStable
Peak12.4yr
Flagship product driving 63% of company revenue; long exclusivity runway (15+ years) provides sustained cash generation.
Help build intelligence for Alkermes
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.